Farmakogenomika alergii
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
sie 6, 2012
Słowa kluczowe:
farmakogenomika, alergia, histamina, astma
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rozwój farmakogenomiki stwarza szansę na zwiększenie efektywności leczenia w oparciu o mapę genetyczną pacjenta. Poniżej opisano dotychczasowe wyniki dotyczące zmienności genetycznej enzymów i receptorów będących celami w farmakoterapii alergii. Przywołano szereg przykładów, takich jak receptor histaminowy i β2-adrenergiczny, w których farmakogenomika znalazła zastosowanie.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pera , Łukasz, & Białek , S. (2012). Farmakogenomika alergii. Alergoprofil, 8(3), 16-19. Pobrano z https://journalsmededu.pl/index.php/alergoprofil/article/view/738
Numer
Dział
Artykuł
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Szefler S.J., Martin R.J., King T.S., Boushey H.A., Cherniack R.M., Chinchilli V.M., Craig T.J., Dolovich M., Drazen J.M., Fagan J.K. et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 2002, 109: 410-418.
2. Lazarus S.C., Lee T., Kemp J.P., Wenzel S., Dube L.M., Ochs R.F., Carpentier P.J.: Safety and clinical efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care 1998, 4: 841-848.
3. Lampiasi N., Azzolina A., Montalto G., Cervello M.: Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp. Mol. Med. 2007, 39: 284-294.
4. Thurmond R.L., Gelfand E.W., Dunford P.J.: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat. Rev. Drug. Discov. 2008, 7: 41-53.
5. Guidelines for reffering to the HapMap populations in publications and presentations.
6. Aichberger K.J., Mayerhofer M., Vales A. et al.: The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood 2006, 108: 3538-3547.
7. Ayuso P., Garcia-Martin E., Martinez C., Agundez J.A.: Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet. Genomics 2007, 17: 687-693.
8. Garcia-Martin E., Garcia-Menaya J., Sanchez B. et al.: Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clin. Exp. Allergy 2007, 37: 1175-1182.
9. Preuss C.V., Wood T.C., Szumlanski C.L. et al.: Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol. Pharmacol. 1998, 53: 708-717.
10. Yan L., Galinsky R.E., Bernstein J.A., Liggett S.B., Weinshilboum R.M.: Histamine N-methyltransferase pharmacogenetics: association of common functional polymorphism with asthma. Pharmacogenetics 2000, 10: 261-266.
11. Fenech A., Hall I.P.: Pharmacogenetics of asthma. Br. J. Clin. Pharmacol. 2002, 53: 3-15.
12. Aziz I., Hall I.P., McFarlane L.C., Lipworth B.J.: B2-adrenoreceptor regulation and bronchodilator sensivity after regular treatment with formoterol in subjects with stable asthma. J. Allergy Clin. Immunol. 1998, 101: 337-341.
13. Martinez F.D., Graves P.E., Baldini M., Solomon S., Erickson R.: Association between genetic polymorphisms of the B2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 1997, 100: 3184-3188.
14. Hall I.P.: Pharmacogenetics of Asthma. Chest 2006, 130: 1873-1878.
15. Dolen W.K.: Pharmacogenetics in clinical allergy. Allergy Clin. Immunol. Int. J. World Allergy Org. 2004, 16: 231-236.
16. Fowler S.J., Hall I.P., Wilson A.M. et al.: 5-Lipoxygenase polymorphism and in vivo response to leukotriene receptor antagonist. Eur. J. Clin. Pharmacol. 2002, 58: 187-190.
17. Meyers D.A.: Genetics of asthma and allergy: what have we learned? J. Allergy Clin. Immunol. 2010, 126(3): 439-446.
18. Thong B.Y.H., Tan T.C.: Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 2011, 71(5): 684-700.
2. Lazarus S.C., Lee T., Kemp J.P., Wenzel S., Dube L.M., Ochs R.F., Carpentier P.J.: Safety and clinical efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care 1998, 4: 841-848.
3. Lampiasi N., Azzolina A., Montalto G., Cervello M.: Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp. Mol. Med. 2007, 39: 284-294.
4. Thurmond R.L., Gelfand E.W., Dunford P.J.: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat. Rev. Drug. Discov. 2008, 7: 41-53.
5. Guidelines for reffering to the HapMap populations in publications and presentations.
6. Aichberger K.J., Mayerhofer M., Vales A. et al.: The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood 2006, 108: 3538-3547.
7. Ayuso P., Garcia-Martin E., Martinez C., Agundez J.A.: Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet. Genomics 2007, 17: 687-693.
8. Garcia-Martin E., Garcia-Menaya J., Sanchez B. et al.: Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clin. Exp. Allergy 2007, 37: 1175-1182.
9. Preuss C.V., Wood T.C., Szumlanski C.L. et al.: Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol. Pharmacol. 1998, 53: 708-717.
10. Yan L., Galinsky R.E., Bernstein J.A., Liggett S.B., Weinshilboum R.M.: Histamine N-methyltransferase pharmacogenetics: association of common functional polymorphism with asthma. Pharmacogenetics 2000, 10: 261-266.
11. Fenech A., Hall I.P.: Pharmacogenetics of asthma. Br. J. Clin. Pharmacol. 2002, 53: 3-15.
12. Aziz I., Hall I.P., McFarlane L.C., Lipworth B.J.: B2-adrenoreceptor regulation and bronchodilator sensivity after regular treatment with formoterol in subjects with stable asthma. J. Allergy Clin. Immunol. 1998, 101: 337-341.
13. Martinez F.D., Graves P.E., Baldini M., Solomon S., Erickson R.: Association between genetic polymorphisms of the B2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 1997, 100: 3184-3188.
14. Hall I.P.: Pharmacogenetics of Asthma. Chest 2006, 130: 1873-1878.
15. Dolen W.K.: Pharmacogenetics in clinical allergy. Allergy Clin. Immunol. Int. J. World Allergy Org. 2004, 16: 231-236.
16. Fowler S.J., Hall I.P., Wilson A.M. et al.: 5-Lipoxygenase polymorphism and in vivo response to leukotriene receptor antagonist. Eur. J. Clin. Pharmacol. 2002, 58: 187-190.
17. Meyers D.A.: Genetics of asthma and allergy: what have we learned? J. Allergy Clin. Immunol. 2010, 126(3): 439-446.
18. Thong B.Y.H., Tan T.C.: Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 2011, 71(5): 684-700.